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The rapid increase in the number of approved therapeutic proteins, including recombinant antibodies,
for diseases necessitating chronic treatments raises the question of the overall costs imposed on
healthcare systems. It is therefore important to investigate alternative methods for recombinant protein
administration. The implantation of genetically engineered cells is an attractive strategy for the chronic
long-term delivery of recombinant proteins. Here, we have developed a high-capacity cell encapsulation
system for the implantation of allogeneic myoblasts, which survive at high density for at least one year.
This ﬂat sheet device is based on permeable polypropylene membranes sealed to a mechanically
resistant frame which conﬁne cells seeded in a tailored biomimetic poly(ethylene glycol) (PEG)-based
hydrogel matrix. In order to quantitate the number of cells surviving in the device and optimize initial
conditions leading to high-density survival, we implant devices containing C2C12 mouse myoblasts
expressing a luciferase reporter in the mouse subcutaneous tissue. We show that initial cell load,
hydrogel stiffness and permeable membrane porosity are critical parameters to achieve long-term
implant survival and efﬁcacy. Optimization of these parameters leads to the survival of encapsulated
myogenic cells at high density for several months, with minimal inﬂammatory response and dense
neovascularization in the adjacent host tissue. Therefore, this encapsulation system is an effective
platform for the implantation of genetically engineered cells in allogeneic conditions, which could be
adapted to the chronic administration of recombinant proteins.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
With the recent expansion of biological drugs including re-
combinant antibodies, an increasing number of therapeutic appli-
cations are based on chronic administration. However, these
treatments face limitations related to the cost of producing com-
plex recombinant proteins, and necessitate repetitive intravenous
injections to achieve sustained therapeutic levels. These constraints
prompt the development of alternative systems to deliver biolog-
ical drugs. The implantation of ex vivo genetically modiﬁed cells
provides a possible alternative for the continuous delivery of re-
combinant proteins. However, it is critical to devise systems to
maintain long-term cell survival and consistent production of the
therapeutic factor, control the dose of protein administered, andSV-BMI-LEN, Station 19, 1015
216939520.
hneider).
All rights reserved.retrieve the implanted cells in case the treatment needs to be
halted. Encapsulated cell technology (ECT) is a promising concept
based on the conﬁnement of the grafted cells within a permeable
device. In ECT, genetically engineered cells are seeded within a
polymer capsule, mainly composed of a permeable membrane,
which protects the grafted cells from any direct contact with the
host immune system, and allows for the diffusion of oxygen and
nutrients. As the implanted cells are partially immunoprotected,
ECT is compatible with allogeneic transplantation. Therefore, a
single characterized source of human cells is applicable to large
cohorts of recipients. ECT has already been translated to clinical
studies, e.g. for the delivery of neurotrophic factors in the eye, the
brain or the spinal cord [1e4].
The engineering of macroencapsulation device for clinical
application has to meet critical requirements. Overall device ge-
ometry determines cell content and thereby the rate of recombi-
nant protein secretion. Also, it is important to achieve high cellular
density inside the device in order to produce therapeutic levels of
the recombinant protein. In addition, long-term survival of cells
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renew inside the device. These aspects critically depend on the
supply of oxygen and nutrients. One approach improving long-term
implant efﬁcacy is to seed the cells at low density, using an artiﬁcial
extracellular matrix allowing for their progressive expansion inside
the device [5]. Capsule engineering and initial conditions at the
time of implantation are critical to promote neovascularization,
which in turn favors the expansion of cells inside the device.
To produce a system applicable to clinical testing, it is essential
to use materials that satisfy the criteria imposed by regulatory
agencies for medical devices. The assembly process has to be highly
reproducible and compatible with large-scale production of a de-
vice with appropriate mechanical properties.
In order to address these questions, we have generated a high
capacity ECT system based on a “ﬂat-sheet” geometry adaptable to
large amounts of transplanted cells. To facilitate the expansion of
the cells inside the internal chamber, cells are mixed with an
adaptable biodegradable polymeric hydrogel inside the device.
Here, we present a systematic in vivo optimization of important
parameters for ECT, including initial cell density, polymer mem-
brane porosity and hydrogel matrix stiffness. Bioluminescence
produced by luciferase-expressing C2C12 myoblasts is used to
longitudinally monitor cells implanted in themacrocapsule [6], and
determine the conditions leading to long-term cell survival inside
the device.
2. Materials and methods
2.1. Device engineering, assembly and quality control
To generate ﬂat sheet devices, an outer polymeric frame, porousmembranes and
reinforcement mesh were assembled by ultrasonic welding. Outer frames were
manufactured by injection molding of USP VI grade medical polypropylene. Un-
supported hydrophilic polypropylene porous membranes (Pall Corporation) and a
77 mmmonoﬁlament polyester mesh (Reichelt Chemietechnik GmbH & Co) were cut
out using an ultrasonic cutting process. The devicewas then assembled in a two-step
process. A ﬁrst ultrasonic welding step sealed the membrane and mesh to the outer
frame to generate one half of the ﬁnal device. The second step tightly sealed two half
pieces together by delivering ultrasounds at the level of the outer frame. For quality
control, the sealing of each device was veriﬁed using an air-leak test. While
immerged in sterile double distilled water, ﬁltered air was injected at a pressure of
17.58 hPa (2.5 Psi) for 5 s. Devices showing pressure decay greater than 100 Pa over
5 s were discarded.
To facilitate the loading of the cells, a 1 ml pipette tip was glued into the loading
port using photopolymerizing medical grade glue (Loctite, Henkel). Assembled de-
vices were gas sterilized with ethylene oxide before further use.
2.2. Cell culture and genetic engineering
The mouse C2C12 myoblast cell line was obtained from American Type Culture
Collection (ATCC) and maintained in regular culture conditions (37 C, 5% CO2) in
Dulbecco’s Modiﬁed Eagle Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), penicillin (100 U/ml) and streptomycin (100 U/ml) (Life Technologies).
Fireﬂy luciferase cDNA was subcloned into the pRRLSIN.cPPT.PGK-GFP.WPRE
lentiviral vector (Addgene plasmid #12252). Lentiviral vector particles pseudo-
typed with the VSVG envelope were used at multiplicity of infection of 1500 to
generate a stable C2C12 cell line expressing luciferase. Further details are described
in Ref. [40].
2.3. PEG hydrogel synthetic matrix
Fibrin-mimicking synthetic hydrogels were formed as described [7] using Factor
XIIIa (FXIIIa)-mediated cross-linking of 8arm-poly(ethylene glycol) (PEG) precursors
end-functionalized with peptidic FXIIIa substrates, namely 8arm-PEG-MMP-Lys
(40 kDa, MMP-Lys: Ac-FKGGGPQGIWGQ-ERCG-NH2, MW: 1717.9 g/mol) and 8arm-
PEG-Gln (40 kDa, Gln: H-NQEQVSPL-ERCGNH2, MW: 1539.6 g/mol) [7,8]. To prepare
300 mL of stoichiometrically balanced ([Lys]/[Gln] ¼ 1) 1.5% w/v gels, 2.1915 mg of
8arm-PEG-Gln and 2.3085 mg of 8arm-PEG-MMP-Lys were prepared in 200 mL Tris
buffered saline (TBS; 50 mM, pH 7.6) containing 50 mM calcium chloride and 100 mM
of the adhesion ligand TG-RGD (H-NQEQVSPL-RGDSPG-NH2; MW: 1539.6 g/mol).
95 ml of cell suspension was added to this precursor solution, and crosslinking was
induced by adding 5 mL thrombin-activated FXIIIa (200 U/mL; FibrogamminP from
CSL Behring).2.4. Device loading and implantation
Under sterile conditions, C2C12 myoblasts were harvested with 0.05% trypsine
EDTA solution (Life Technologies) and resuspended in SKBM serum free myoblast
culture medium (Lonza) after cell counting. Cell suspension (95 ml) was mixed to gel
precursor solution as described above. Immediately after addition of FXIIIa, 250 ml of
the mix was loaded into the device using a 1 ml pipette. As the injected volume
exceeded the inner volume of the device, a fraction of the total volume was ultra-
ﬁltrating through the porousmembrane. Each devicewas placed in a 15ml sterile tube
on a rocking platform for about 5 min until gelation was initiated, and was incubated
for 30e45min at 37 C until complete gelation. The loading port was then cut out and
the device was sealed with photo polymerizing medical-grade glue (Loctite, Henkel).
The devicesweremaintained in 2ml SKBM (6-well plate) for 24 h before implantation.
All experiments on animals were done according to the Swiss regulation on
animal experimentation and the European Community Council directive (86/609/
EEC) for the care and use of laboratory animals. Animals had access to water and
food ad libitum. Adult B6-albino C57BL/6J-Tyrc-2J/J female mice were anesthetized
with isoﬂurane and devices were implanted on the back of the animal, in the sub-
cutaneous tissue. Thewoundwas closedwith surgical staples and animals recovered
in their home cage. Analgesia was provided by acetaminophen 2 mg/ml in drinking
water for three days.
2.5. Detection of luciferase activity in vitro
To quantify luciferase expression from C2C12 cells, serial dilution of cells were
plated in quadruplicates in a 96-well plate. The day after, shortly before analysis,
conditioned medium was removed and fresh prewarmed medium containing
150 mg/ml D-luciferin (Biosynth) was applied. Repeated measurements were done
on IVIS Spectrum imaging system (PerkinElmer) until signal reached a plateau.
Immediately after acquisition, cells were harvested with trypsin-EDTA and counted
using an automated cell counter (Countess, Invitrogen). To measure luciferase ac-
tivity from cells inside devices in vitro, devices were placed into culture medium
containing 150 mg/ml D-luciferin and scanned using a similar protocol.
2.6. Bioluminescence monitoring in vivo
Every twoweeks, in vivo imaging was performed with an IVIS Spectrum imaging
platform (PerkinElmer). The mice were injected intraperitoneally with ﬁltered
150 mg/kg D-luciferin in sterile PBS, placed in the imaging chamber and scanned
under isoﬂurane anesthesia. For each time point, one mouse was selected randomly
to determine the time of peak distribution. For this animal, imaging was repeated
every 3 min until the ﬂux of emitted photons reached a plateau, which was used to
deﬁne the time of peak distribution. The remaining cohort of mice was scanned at
the same interval post-luciferin injection. Data were analyzed with Living Image
Software (PerkinElmer) by delimiting a constant region of interest (ROI, ﬁxed area)
around the device and quantifying total radiance in photon/sec/cm2/sr.
2.7. Histological analysis of explanted devices
At the end of experiment, mice were sacriﬁced by an overdose of pentobarbital.
Shortly after, devices were dissected and retrieved. Device were then ﬁxed in 4%
paraformaldehyde overnight at 4 C, dehydrated and processed for parafﬁn embed-
ding. Sampleswere sliced on amicrotome at a thickness of 3 mm. Sectionswere stained
with Masson’s trichrome or hematoxylin and eosin. To identify endothelial cells,
immunohistochemistry against murine CD31 (rat anti-mouse CD31, clone SZ31, Dia-
nova) was performed according to antibody manufacturer protocol. Brieﬂy, sections
were deparafﬁnized in toluol for 10min and rehydrated inwater. Antigen retrievalwas
performed in 10mM citrate buffer pH 6.0 for 20min at 95 C. After 10minwash in PBS,
endogenous peroxidases were quenched with H2O2 3% for 10 min at room tempera-
ture (RT) and blocking buffer (3% BSAþ 5% rabbit serum in PBS) was applied for 1 h at
RT. Anti-mouse CD31 was incubated 1/50 in blocking buffer overnight at 4 C. Bio-
tinylated rabbit anti-rat IgG (Vector Laboratories) was applied 1/200 for 1 h at RT for
DAB revelation. Counterstain was performed with Harris hematoxylin.
2.8. Statistical analysis
Data are expressed as average  standard error of the mean (SEM). Statistical
analysis was performed using the Statistica software (StatSoft Inc.). The alpha level
of signiﬁcance was set at 0.05. One-way ANOVA or two-way repeated measures
ANOVA with Fisher LSD post hoc analysis were performed.
3. Results
3.1. Device assembly by ultrasonic welding
In order to maximize the amount of cells surviving within a
macroencapsulation device, we engineered a high capacity capsule
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was chosen to allow for large inner volume and facilitate implanta-
tion in the subcutaneous tissue. This design also provides large areas
of permeable polymer membrane to maximize diffusion of oxygen
and nutrients formetabolically supporting the cells inside the device.
In order to reduce the distance between the grafted cells and host
blood vessels, we used hydrophilic polypropylene membranes
(w100 mm thick) and minimized inter-membrane spacing (100e
300 mm). A major element in device design is an outer polymeric
frame, which confers mechanical resistance and seals the mem-
branes together. Membranes and frame are composed of thermo-
plastic polypropylene, a material compatible with ultrasonic
welding. This technologywas used for the tight and precise assembly
of the device, including polyester reinforcement meshes apposed on
the outer sides of the device (Fig. 1A). An energy director was
implemented to focus the ultrasounds and guaranty welding tight-
ness. Scanning electronmicroscopy conﬁrmed the completemerging
of the different elements following ultrasonic welding (Fig. 1B). We
also veriﬁed that the ultrastructure of the porousmembranewas not
altered by exposure to ultrasounds (Fig. 1C). The overall dimensions
of the implant were 27 mm long, 12 mm wide and 1.2 mm thick. A
port was integrated in the outer frame for loading the cells. Once the
cells were loaded inside the capsule, the port was cut out and the
device sealed with glue prior to implantation (Fig. 1D). Before utili-
zation, all devices were quality controlled using an air-leak test and
defective devices (<10%) were discarded.Fig. 1. Flat sheet cell encapsulation device. (A) Schematic cross-sectional view of the frame s
ultrasonic welding is applied. Ultrasonic welding is ﬁrst used to assemble one half of the poly
in red) and the hydrophilic polypropylene porous membrane (PM, in green). In the secon
director (ED). (B) Scanning electron microscopy of a cross-section of the supporting frame a
sealing of the polyester reinforcement mesh in the welded polypropylene of the membran
polypropylene porous membrane, before and after the welding process. Note that exposur
Macroscopic view of the assembled ﬂat sheet device showing the peripheral transparent sup
implantation, after removal of the loading port and sealing with glue. Scale bar: 10 mm.3.2. Internal degradable artiﬁcial ECM
Previous studies have shown that initial seeding of the capsule
with cells at low density is critical to allow for proper engraftment
[5]. The purpose of this approach is to avoid early metabolic failure
in poorly vascularized conditions following device implantation.
Later on, the surviving cells will expand as a function of oxygen and
nutrient supply. This process might be facilitated over time as
neovascularization develops. Because most cell lines compatible
with long-term survival within an encapsulation device are
adherent, it is essential to provide the cells with an artiﬁcial
extracellular matrix (ECM) which will support their expansion and
three-dimensional colonization of the device inner space. As the
degradation of natural ECM components including collagen and
laminin can produce foreign antigenic elements diffusing outside
the device, it is preferable to instead develop alternative systems.
Cells targeted for encapsulation can be mixed with a hydrogel
precursor solution that is crosslinked shortly after loading in the
ﬂat sheet device to form a hydrogel network. To this end, we used a
PEG-based hydrogel matrix. Furthermore, PEG is conjugated with
peptides bearing a matrix metalloproteinase (MMP) substrate for
progressive, cell-mediated degradation, as well as an RGD motif
enabling cellular adhesion [8].
To determine how cells expand in the encapsulation device
following implantation, we used the C2C12 myoblasts, a cell line
that has successfully been used in preclinical models usingystem used to assemble the device components. The arrows indicate the places where
propylene supporting frame (SF, in blue), the outer polyester reinforcement mesh (RM,
d step, both halves of the supporting frame are assembled together using the energy
fter ultrasonic welding. Note the tight assembly of the two halves of the frame and the
e and frame. Scale bar: 250 mm. (C) Scanning electron microscopy of the hydrophilic
e to ultrasounds does not cause any damage to the membrane. Scale bar: 10 mm. (D)
porting frame, connected to the loading port. The lower picture shows a device prior to
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proteins [5,9,10]. C2C12 myoblasts were encapsulated in ﬂat sheet
devices using a modiﬁed PEG hydrogel as a matrix, and implanted
in the mouse subcutaneous tissue. After one week, histological
analysis of explanted capsules showed clusters of viable C2C12 cells
within the hydrogel present in the center part of the device, and
cells organized in dense layers close to the porous membranes
(Fig. 2A,B). Some hydrogel ﬁltering through the porous membranes
during the loading procedure was also found on the outside of the
capsule, scattered among the reinforcement mesh. As soon as 3
weeks post-implantation, the hydrogel outside the capsule was
almost completely degraded (Fig. 2C,D). This rapid elimination ofFig. 2. The PEG hydrogel matrix is progressively degraded in vivo. (AeF) Photomicrographs
Devices loaded with 1  106 C2C12 myoblasts and 1.5% w/v PEG hydrogel matrix are analy
subcutaneous tissue. The presence of PEG hydrogel is indicated with arrowheads. Note the
density inside the device. Scale bar: 100 mm (A,C,D) and 50 mm (B,D,F). White asterisk: polthe PEG matrix is consistent with high MMP catalytic activity,
which is likely to be induced by wound healing and tissue-
remodeling around the implant. Inside the device, dense hydrogel
scattered in small areas was still visible at 3 weeks, but almost
disappeared after 6 weeks in vivo (Fig. 2E,F). C2C12 myoblasts
progressively expanded within the implant in parallel to matrix
degradation.
3.3. Monitoring of cell survival using the luciferase reporter
In order to establish pre-implantation conditions leading to
long-term, high-density survival of cells in the ﬂat sheetof histological sections across ﬂat sheet devices, stained with hematoxylin and eosin.
zed at 1 week (A,B), 3 weeks (C,D) and 6 weeks (E,F) post-implantation in the mouse
progressive degradation of the PEG gel over time, corresponding to an increase in cell
ypropylene porous membrane; black asterisk: location of the polyester mesh.
Fig. 3. Luciferin-induced light signal intensity is an indicator of the load of luciferase-expressing cells inside the device. (A) Lentiviral vector construct used to generate C2C12 cell
lines stably expressing luciferase. (B) Heat map of photon emission by engineered C2C12 myoblasts seeded at different densities (0e5  104 cells per well). (C) Quantiﬁcation of the
photon ﬂux from individual wells shows a linear correlation with the number of cells. Data are expressed as mean of quadruplicates  SD. (D) Heat map of photon emission in a
device loaded with C2C12 myoblasts expressing luciferase. (E) Quantiﬁcation of photon ﬂux from devices loaded with different cell densities (6  104e3  106 cells per device)
shows linear correlation. Data are expressed as mean  SD; N ¼ 10. (F) Representative heat maps of photon emission in the same mouse at various time points, up to 19 weeks after
subcutaneous implantation of a ﬂat sheet device containing luciferase-expressing C2C12 myoblasts.
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previously described [6]. A stable C2C12 cell line expressing the
ﬁreﬂy luciferase under the pgk-1 promoter was generated by len-
tiviral transduction (Fig. 3A). Cells plated at different densities
produced detectable bioluminescence following addition ofluciferin in the culture medium (Fig. 3B). Quantiﬁcation of emitted
light revealed a linear relationship with the amount of living cells in
each well (Fig. 3C). To verify that light could be effectively trans-
mitted through the encapsulating membrane and mesh, similar
measurements were performed on ﬂat sheet devices loaded with
Fig. 4. Soft PEG hydrogel allows for long-term survival of C2C12 myoblasts at high cell density. (A) Longitudinal quantiﬁcation of luciferase-induced light signal in mice implanted
with ﬂat sheet devices loaded with 3 different PEG gel conditions. Flat sheet devices with 0.45 mm membrane pore size are initially loaded with 1  106 cells luciferase-expressing
C2C12 myoblasts. Data are expressed as mean  SEM; N ¼ 10. Two-way repeated-measures ANOVA with Fisher LSD post hoc test: *p < 0.05. (B) Quantiﬁcation of light signal 9
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(Fig. 3D). We indeed found the same relationship between the
number of encapsulated cells and the measured ﬂux of emitted
photons (Fig. 3E). Hence, the same luciferase reporter system could
be used to monitor the expansion and survival of encapsulated cells
in vivo, by quantifying luciferin-induced bioluminescence in mice
subcutaneously implanted with ﬂat sheet devices (Fig. 3F). In the
next series of experiments, we used this semi-quantitative
approach to optimize three parameters that are key to cell sur-
vival inside the device: (1) the hydrogel polymer content, (2)
membrane porosity and (3) the initial cell seeding density.
3.4. Artiﬁcial ECM stiffness
The presence of a synthetic ECM inside the device is an impor-
tant factor for the early adaptation and expansion of cells after
implantation. Synthetic hydrogel can be tailored for cell-speciﬁc
requirements. Indeed, it has been demonstrated that the PEG
hydrogel stiffness, which can be readily modiﬁed by altering the gel
precursor concentration, affects cell proliferation and differentia-
tion [11,12]. To test the effect of gel stiffness on the cell expansion
rate and survival of C2C12 myoblasts inside the device, we tested
two different PEG gel concentrations. We compared devices (pore
size 0.45 mm) loaded with same amount of luciferin-expressing
cells (1  106 C2C12 myoblasts) either in the absence of hydrogel
matrix, with 1.5% w/v PEG hydrogel or with 3% w/v PEG hydrogel,
corresponding to a Young’s modulus of 424.732  95.76 Pa (termed
‘soft’ gel for simplicity) and 2558.91  48.94 Pa (‘stiff’ gel),
respectively. For each condition, we repeatedly measured the
bioluminescence produced in living animals, as a proxy for the
amount of bioactive cells contained in the implanted devices
(Fig. 4A; note that for the sake of comparison, the radiance data of
the test group with 1  106 cells, 1.5% PEG and 0.45 mm porous
membranes are also shown in Fig. 5A and D). During the ﬁrst seven
weeks after implantation, we could detect bioluminescence for all
three conditions. During this period of time, the intensity of the
signal did not increase over time, and only minor variations were
measured between the tested conditions. In the second phase of
implantation (week 7e19), we observed a clear progression in the
intensity of the bioluminescence signal produced. In the absence of
any hydrogel matrix, a rapid expansion occurred between week 7
and 9, and the intensity of the emitted light was signiﬁcantly higher
at week 9 than in any of the other conditions (Fig. 4B). However,
signal intensity did not further increase (Fig. 4A). Histological
analysis of devices explanted at week 19 revealed disorganized cell
clusters in some sections of the inter-membrane inner space, with
large necrotic zones bordered by few living myoblasts (Fig. 4C,D).
With both soft and stiff gels, the progression of the biolumi-
nescence signal was very similar until week 9 (Fig. 4A,B). However,
fromweek 17 on, signal intensity further increased only in capsules
loaded with soft hydrogel, reaching signiﬁcantly higher values than
in any of the other two conditions (Fig. 4A). Histological analysis
revealed a highly dense mass of viable cells in this condition,
conﬁrming that enhanced bioluminescence reﬂects high cell sur-
vival inside the device (Fig. 4E). C2C12 myoblasts formed aligned
clusters of cells indicative of myogenic differentiation (Fig. 4E,F). In
contrast, the viability of the cells was reduced in devices initially
loaded with 3% PEG hydrogel, suggesting that the matrix was tooweeks after implantation. Note the transiently higher level of light emission in devices w
Representative photomicrographs showing a device loaded without PEG scaffold 19 weeks a
few viable C2C12 myoblasts (arrowheads). (E,F) Representative photomicrographs of a devic
cell density and the presence of elongated myoblast cells that are either longitudinally (
photomicrographs of a device initially loaded with stiff PEG hydrogel 19 weeks after implan
(arrows). Masson’s trichrome staining. Scale bars: 100 mm (C,E,G), 50 mm (D,F,H). Asterisk:stiff in this condition to support efﬁcient expansion of C2C12
myoblasts (Fig. 4G,H). Indeed, we found the presence of intact
hydrogel patches even after 19 weeks in vivo. Overall, we found in
this long-term experiment that soft hydrogel is the optimal con-
dition to support encapsulated C2C12 myoblast expansion in vivo.
3.5. Membrane permeability and initial cell density
We further tested in parallel experimental groups the effect of
membrane porosity and initial cell load on the outcome of C2C12
myoblasts implanted in ﬂat sheet devices. The physical character-
istic of the porous membrane is a critical parameter for the survival
of encapsulated allogeneic cells. Porosity deﬁnes the rate of passive
molecule diffusion across themembrane, which includes the inward
diffusion of oxygen and nutrients, and the outward release of soluble
factors. While inward diffusion is critical for metabolic supply to the
implanted cells, factors released by the capsule might elicit an im-
mune response. Additionally, membrane permeability has been
proposed to affect the quantity of recombinant proteins delivered by
macroencapsulation implants [13]. We compared the long-term
survival of luciferase-expressing cells encapsulated using two
types of polypropylene membranes, with pore sizes of either
0.22 mm or 0.45 mm (Fig. 5AeC). Capsules were loaded with 1 106
C2C12 myoblasts with a soft PEG hydrogel. Bioluminescence was
similar between the two conditions over the ﬁrst 7 weeks post-
implantation, and steadily increased in both conditions for the
following 10 weeks (Fig. 5A). After 17 weeks, the bioluminescence
signal in devices made of the 0.22 mm porous membranes started to
decline. Remarkably, the light signal produced by the devicemade of
the most porous membrane increased more consistently and
reached signiﬁcantly higher values at week 19. Histological analysis
of the explanted devices revealed necrotic zones in the devices
madewith the 0.22 mmporous membranes, especially in the central
part of the cell mass where metabolic supply is most limited
(Fig. 5B). In contrast, a thick layer of viable cells was found inside the
0.45 mm-porous device (Fig. 5C). Therefore,membraneswith smaller
porosity are likely to limit the diffusion of oxygen and nutrients,
which may fail to support the survival of the encapsulated cell mass.
Another approach to tune cell expansion as a function of oxygen
and nutrient supply is to adapt the initial loaded cell density. We
tested 3 different initial cell concentrations, 0.3, 1 and 3  106 cells.
Cells were loaded with soft PEG hydrogel into devices assembled
with 0.45 mm pore-sized membranes. The in vivomonitoring of cell
growth showed signiﬁcant differences between these conditions
(Fig. 5D). With an initial load of 0.3  106 cells, the signal stabilized
after 9 weeks and there was no further expansion phase. In
contrast, a steady increase was observed in the group loaded with
1  106 cells. Although capsule viability was excellent in both
groups, the ﬁnal cell density inside the device was lower in the
capsules initially containing 0.3  106, as compared to 1 106 cells
(compare Fig. 5E with C).
As expected, an initial load of 3  106 cells produced a more
intense bioluminescence during the ﬁrst 7 weeks (Fig. 5D). How-
ever, the signal did not further increase until week 19. Histological
analysis revealed the presence of necrotic “ghost” cells inside the
device (Fig. 5F). This necrosis is likely caused by initial cell overload,
which was not adapted to restrictive metabolic conditions during
the initial phase of implantation.ithout any PEG matrix. Mean  SEM, N ¼ 10. One-way ANOVA: ***p < 0.001. (C,D)
fter implantation. Note the presence of the large necrotic core (arrows) surrounded by
e initially loaded with soft PEG hydrogel after 19 weeks of implantation. Note the high
arrow) or transversally (arrowhead) oriented inside the device. (G,H) Representative
tation. Note the presence of undigested hydrogel (arrowhead) and necrotic C2C12 cells
polypropylene porous membrane.
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When loading parameters were set at an initial amount of
1106 cells using a soft hydrogel matrix, we achieved high-densityFig. 5. Membrane permeability and initial cell density are critical factors for long-term sur
mice implanted with ﬂat sheet devices to compare the efﬁcacy of membranes with pore siz
the larger pore size. Data are expressed as mean  SEM; N ¼ 10. Two-way repeated-mea
crographs comparing cell density inside devices at 19 weeks post-implantation: 0.22 mm (B
core (arrow) and sparse viable cells close to the membrane (arrowheads). (D) Luciferase sign
function of the initial cell load. Data are expressed as mean  SEM; N ¼ 10. Two-way repeat
photomicrographs of devices loaded with either 0.3  106 or 3  106 cells. Note the high via
contrast, high initial load (3  106 cells) leads to a necrotic core of cells (arrow) with only
50 mm.survival of myoblasts inside 0.45 mm porous membranes. Histo-
logical analysis of the capsules at 19 weeks post-implantation
revealed dense alignment of structures resembling myoﬁbers
formed by elongated C2C12 cells (Fig. 6A). Myoﬁbers werevival of encapsulated cells. (A) Monitoring of luciferase-mediated bioluminescence in
es of either 0.22 mm or 0.45 mm. Note the signiﬁcantly increased bioluminescence with
sures ANOVA with Fisher LSD post hoc test: *p < 0.05. (B,C) Representative photomi-
) or 0.45 mm (C) pore-sized permeable membranes. Note the presence of a necrotic cell
al in mice implanted with ﬂat sheet devices (1.5% PEG hydrogel, 0.45 mm pore size) as a
ed-measures ANOVA with Fisher LSD post hoc analysis: *p < 0.05. (E,F). Representative
bility and low density of C2C12 myoblasts in the capsule loaded with 0.3  106 cells. In
sparse viable C2C12 myoblasts (arrowheads). Masson’s trichrome staining. Scale bar:
Fig. 6. Optimized loading conditions allow for long-term survival of encapsulated C2C12 cells at high density. (A) Representative photomicrographs of devices 19 weeks after
subcutaneous implantation in mice. Masson’s trichrome staining reveals viable cells inside the device and collagen-containing ECM. Note the high cellular density and secreted
collagen extracellular matrix (blue staining). (B) Higher magniﬁcation of a hematoxylin and eosin staining, showing the presence of striations in C2C12 cells (arrow) indicative of
terminal muscle differentiation. (C,D) Representative photomicrographs of devices demonstrating high density of viable cells, 13 months after implantation in mice. Scale bars:
25 mm (A,D), 10 mm (B), 50 mm (C).
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trichrome staining and was therefore mainly composed of collagen
ﬁbers (Fig. 6A,B). C2C12myoblasts were therefore able to produce a
dense supporting ECM following initial expansion in the PEG ma-
trix and MMP-mediated degradation of the hydrogel. This micro-
environment favored differentiation of C2C12 myoblasts into
striated myoﬁbers, as revealed by hematoxylin and eosin staining
(Fig. 6B). In a parallel chronic experiment based on the same con-
ditions, histological analysis of devices retrieved after 13 months
in vivo revealed a high density of surviving cells (Fig. 6C,D).
Therefore, encapsulated myoblasts can long-term survive in the
subcutaneous tissue.
3.7. Neovascularization
As described above, the access to oxygen and nutrients is a
limiting factor, which directly affects the survival and expansion of
the cells inside the encapsulating device. Oxygen and nutrient
supply is primarily determined by the neovascularization that de-
velops in close proximity to the implanted device. In the previous
experiment, optimal conditions for implantation led to long-term
survival of cells at high density in the ﬂat sheet macro-
encapsulation device. Strikingly, a very dense neovascularization
developed around the implants. Fig. 7A shows a representative
image of the blood vessels present on the ventral side of the device,19 weeks post-implantation. The reinforcement mesh provided a
support for the growth of new blood vessels, penetrating through
the mesh towards the porous membrane (Fig. 7B). Histological
sections of the tissue lining the device conﬁrmed the presence of a
dense network of capillaries near the polymer membrane
(Fig. 7C,D). Immunostaining for the angiogenesis marker CD31
conﬁrmed the proliferation of endothelial cells adjacent to the
membrane (Fig. 7E,F).
3.8. Subcutaneous tissue reaction
Next, we assessed the local host tissue reaction around the
implant to verify its biocompatibility. After one week in vivo, some
PEG hydrogel was still present on the outside of the membrane,
around the reinforcement mesh (Fig. 8A). Few ﬁbroblast-like host
cells were found in the hydrogel, indicative of ongoing tissue
remodeling. At 6 weeks, a typical foreign body response was
observed, as demonstrated by numerous fused macrophages (also
referred to as foreign-body giant cells) coating the mesh and the
permeable membrane (Fig. 8B). We did not observe any signiﬁcant
lymphocytic inﬁltration around the implant, which would have
indicated an activation of chronic inﬂammation. Of note, micro-
vasculature sprouting was already present after 6 weeks in vivo
(Fig. 8B). In contrast to the minimal reaction observed around
viable implants, we noticed the formation of a thick avascular
Fig. 7. Flat sheet device implantation attracts diffuse neovascularization. (A) Representative macroscopic view of a device in situ, 19 weeks after implantation in the mouse sub-
cutaneous tissue. (B) Higher magniﬁcation showing blood vessels crossing the polyester reinforcement mesh (arrows) to form a dense capillary network close to the underneath
porous membrane (arrowheads). (C,D) Histological analysis (Masson’s trichrome staining) shows the dense presence of blood vessels in the surrounding tissue, in particular be-
tween the mesh and the porous membrane (arrows). Scale bar: 50 mm (E,F) Immunohistochemistry for the CD31 endothelial marker conﬁrms dense vascular sprouting. Scale bar:
100 mm (E), 50 mm (F). Dashed line: porous membrane; asterisk: reinforcement mesh (lost during tissue processing).
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exempliﬁed by a device initially loaded with 3  106 cells analyzed
at 19 weeks post-implantation (Fig. 8C). This ﬁbrotic capsule is
subsequent to a persistent reaction against foreign material [14]
and is typically leading to device failure, for instance by
decreasing the diffusion of metabolites [15,16]. At 19 weeks after
implantation, devices containing viable cells were still surrounded
by highly vascularized tissue, with a loose network of collagen ﬁ-
bers consistent with successful capsule engraftment (Fig. 8D).4. Discussion
The delivery of recombinant proteins using allogeneic encap-
sulated cellular transplants has considerable potential as an alter-
native to the administration of biotechnologically produced drugs.
Here, we have generated an innovative cell encapsulation system
comprising an internal chamber for immunoisolating large amount
of cells. Ultrasonic welding technology is used to assemble polymer
permeable membranes, a reinforcement external mesh and a
Fig. 8. Tissue response and biocompatibility of the ﬂat sheet encapsulation device. (A) Representative photomicrograph showing the host subcutaneous tissue response one week
after implantation. Note the presence of intact PEG hydrogel between the mesh and the porous membrane (arrowhead). Dashed line: border of the porous membrane (lost during
tissue processing). (B) At 6 weeks post-implantation, there is activation of a typical foreign body response, with the presence of multinucleated giant cells (arrowheads) adjacent to
the reinforcement mesh and porous membrane. Note the presence of numerous capillaries (arrows). (C) At 19 weeks after implantation, a capsule initially loaded with 3  106 cells
contains extensive necrotic zones (arrows). Note the presence of a thick layer of organized collagen ﬁbers in the surrounding tissue (arrowhead). (D) Tissue response adjacent to a
highly viable capsule, 19 weeks after implantation. Note the dense capillary bed (arrow), the lose presence of collagen ﬁbers and persistence of giant cells (arrowhead). Scale bar:
50 mm (A,B,D), 100 mm (C). Staining: hematoxylin and eosin (A,B) and Masson’s trichrome (C,D). Asterisk: reinforcement mesh (partially lost during tissue processing).
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manufacture. Each part of the device is made of medical grade
material applicable to clinical development. Here, we describe a
capsule devised for implantation in themouse subcutaneous tissue.
Nevertheless, the architecture of the device is readily adaptable to
human applications.
It is critical to establish an approach to homogenously distribute
the cells seeded inside the device, using an artiﬁcial scaffold as a
support to favor their expansion. To address this challenge, cells are
mixed with an injectable PEG hydrogel with adaptable biological
and biophysical characteristics. PEG hydrogel can be tailored for
each cell type, for instance by changing PEG concentration to adapt
gel stiffness, by adding RGD motifs for integrin binding, or by
including MMP domains to make the gel biodegradable [11]. This
matrix can support the growth of various cell types such as ﬁbro-
blasts, osteoblasts or adenocarcinoma cells [11,17,18]. Here, we
show that biodegradable PEG hydrogel is an effective three-
dimensional scaffold for the colonization of the device by C2C12
myoblasts seeded at low density. At an initial concentration of 1.5%
w/v, the soft PEG hydrogel is almost completely degraded over
three weeks. The initial scaffold promotes the alignment of C2C12
myoblasts into myoﬁber-like structures, which ultimately produce
their own ECM mainly constituted of a complex collagen network.In the present study, we show that the initial loading parame-
ters determine the long-term outcome of encapsulated cells
following implantation. One major determinant for long-term cell
viability is the local immune reaction, which can be triggered if
encapsulated cells die and liberate substantial amounts of intra-
cellular soluble antigens diffusing across the permeable membrane
[19]. Some of these antigens, including extracellular ATP [20] or
high-mobility group box 1 protein (HMGP1) [21], can potentially
trigger the rejection of the encapsulated graft via an immune
process involving the production of cytokines, antibodies or nitric
oxide. Preventing early cell death is therefore a priority. The pres-
ence of necrotic zones in the central part of encapsulated cell mass
typically indicates impaired access to oxygen and nutrients
[5,22,23]. The oxygen supply to encapsulated cells depends on
partial oxygen pressure in the blood and surrounding tissue,
proximity to blood vessels, rate of oxygen diffusion into the device,
and the rate of oxygen consumption by the cells inside the device.
We have found that initial conditions are critical for the concerted
proliferation of the encapsulated cells and the development of
neovascularization. When cells are loaded at too high density or in
the absence of any artiﬁcial scaffold, there is rapid expansion in
dense cell clusters and formation of a necrotic core during the ﬁrst
weeks of implantation, leading to poor engraftment. Under
A. Lathuilière et al. / Biomaterials 35 (2014) 779e791790optimized conditions, the growth of cells inside the device parallels
the remodeling of host tissue around the capsule and thereby al-
lows for long-term cell survival at high density.
Surprisingly, several months are needed until the cell mass in-
side the device reaches a steady state. Therefore, longitudinal
assessment by quantiﬁcation of bioluminescence is instrumental to
establish initial loading parameters. When compared to the
approximate 12e20 h doubling time of C2C12 cells in the culture
dish, the kinetic of cell expansion inside the device is unexpectedly
slow. It is likely that hypoxia inside the implanted device affect
myoblast proliferation. Indeed, hypoxia-inducible factors such as
HIF-1a inhibit cell-cycle progression through modulation of p21
and p27 transcription and Rb phosphorylation [24]. Hypoxia-
induced cell-cycle arrest in G1 phase is however transient in
muscle cells, as cell proliferation will resume when normoxia is
restored [25]. Under limited oxygen supply, terminal differentiation
of C2C12 cells into myoﬁbers is transiently repressed in vitro, as a
function of the degree of hypoxia [26]. Myoblasts have nonetheless
the capacity to adapt to hypoxic conditions and recover myogenic
potential. This could explain why encapsulated C2C12 form myo-
ﬁbers following long-term implantation, consistent with the likely
increase in oxygen supply promoted by dense neovascularization at
later stages. This illustrates the remarkable capacity of engineered
C2C12 mouse myoblasts to adapt to restrictive conditions in
encapsulation devices, while maintaining a high level of recombi-
nant protein production in vivo (see Ref. [40]) [27,28].
In order to transfer this technology to humans, similar renew-
able sources of human myogenic cells will need to be identiﬁed for
allogeneic transplantation. Stem cells could provide an expandable
source of myogenic human cells applicable to cell encapsulation.
Human mesenchymal stem cells (hMSCs) can be obtained from
several sources like bone marrow or adipose tissue and have a high
expansion capacity ex vivo [29]. They have been approved for
testing in humans (more than 300 registered trials at www.
clinicaltrials.gov) and can be produced under controlled condi-
tions [30]. Myogenic differentiation was described in vitro and
in vivo [31,32]. Moreover, their ability to express a therapeutic
protein after lentiviral transduction has been shown extensively
[33e37] (see Ref. [40]). Interestingly, the capacity of hMSCs to
respond positively to hypoxia and nutrient deprivation together
with their ability to express angiogenic factors was recently re-
ported [38,39]. Altogether, hMSC is a promising candidate cell type
for the application of cell encapsulation to humans.5. Conclusion
In order to advance cell encapsulation technology towards
clinical application, we report the development of a cell macro-
encapsulation system based on a high-capacity immunoisolation
device combined with an injectable artiﬁcial extracellular scaffold.
Initial hydrogel concentration, cell load and membrane porosity,
are critical factors for the long-term survival of encapsulated allo-
geneic myoblasts at high density in the subcutaneous tissue.Acknowledgments
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